tbuckley/cabot-search huggingface dataset:
Cell-cycle complete response after neoadjuvant letrozole predicts superior relapse-free and overall survival: Long-term follow- up of the letrozole P024 study
Authors: M. J. Ellis, Y. Tao, A. S. Bhatnagar, H. Chaudri Ross, D. Evans, W. R. Miller, W. Eiermann
Journal: Journal of Clinical Oncology (2007)

570 Background: The P024 study was a double blind randomized endocrine therapy trial that compared 16 weeks of letrozole 2.5 mg daily (LET) with tamoxifen 20 mg daily (TAM). LET proved to be more effective than TAM in terms of tumor response and rates of breast conservation therapy (1). Biomarker studies also indicated that LET was a more effective anti-proliferative agent, with greater declines in Ki67 values (2). However, in the P024 trial patients experienced a very low rate of pathological complete response (pCR). We have therefore proposed that a cell-cycle complete response (CCCR - in which tumor cell Ki67 staining is 1% or less in the surgical specimen) may be an alternative to pCR because CCCR indicates that the endocrine therapy was maximally effective in causing cell-cycle arrest. In initial studies we had already shown that CCCR is more common with LET than TAM (3), and also there was a strong association between the absence of a CCCR and the presence of HER2 gene amplification (4). In this study we examined the relationships between CCCR and relapse-free and overall survival. Methods: Per protocol, patients were followed yearly for breast cancer relapse, all cause mortality and breast cancer specific mortality. Relapse-free and breast cancer specific survival was examined according to CCCR status after patients had been followed for five years on adjuvant TAM. Results: Patients who received neoadjuvant LET and whose tumors exhibited a CCCR had superior relapse-free (log rank P=0.0077) and breast cancer specific survival (P=0.0006). Patients who received TAM with a CCCR had superior RFS (P=0.0224) but not breast cancer specific survival. Conclusions: This study supports the conclusion that CCCR may be a clinically useful measurement for patients who undergo neoadjuvant LET. The value of CCCR after neoadjuvant TAM is less clear. A prospective trial that incorporates information on CCCR into clinical decision making regarding adjuvant chemotherapy may be appropriate. 1. Ann Oncol 12, 1527–32 (2001) 2. Cancer Res 63, 6523–31 (2003). 3. J Steroid Biochem Mol Biol 95, 91–5 (2005). 4. J Clin Oncol 24, 3019–25 (2006). No significant financial relationships to disclose.
Subgroup Claims Are Hype, Not Hope
Authors: Alain Braillon
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
GW28-e0443 The extract of Syringa pinnatifolia Hemsl., one of representative folk Mongolian medicine, exerts anti-myocardial ischemia through anti-apoptosis mediated by P53 pathway in mice
Authors: Xiao Feng, Feng Zhao, Ruifeng Bai, Ruifei Zhang, Yuan Cao, Pengfei Tu, Xingyun Chai
Journal: Journal of the American College of Cardiology (2017)
Adjuvant chemotherapy in pT1ab node-negative triple negative breast carcinomas: Results of a national multi-institutional retrospective study
Authors: A. De Nonneville, A. Gonçalves, C. Zemmour, M. Cohen, J.M. Classe, F. Reyal, P.E. Colombo, E. Jouve, S. Giard, E. Barranger, R. Sabatier, F. Bertucci, J.M. Boher, G. Houvenaeghel
Journal: Annals of Oncology (2017)
CEASE: A novel patient directed electronic smoking cessation platform for cancer patients.
Authors: Jennifer M. Jones, Geoffrey Liu, Peter Selby, Lawson Eng, David Paul Goldstein, Meredith Elana Giuliani
Journal: Journal of Clinical Oncology (2017)

6584 Background: Continued smoking in cancer patients receiving treatment results in decreased efficacy, reduced survival, amd increased risk of recurrence. Despite ASCO and AACR policy statements, routine tobacco use screening and provision of smoking cessation treatment has not been widely implemented in the cancer setting. A paper-based tobacco use screening and clinician-dependent referral program for new ambulatory cancer patients was initiated at Princess Margaret Cancer Centre in 2013 resulting in moderate screen rates but low referral rates. In response, we developed and implemented a tailored patient directed electronic smoking cessation platform (CEASE) which included three elements:1) tobacco use assessment tool; 2) patient education on benefits of cessation; 3) a patient directed automatic referral system to smoking cessation programs. Methods: Interrupted time series design to examine the impact of CEASE on process of care (screening rates, referrals offered and accepted) and patient reported (quit attempts, smoking status, uptake of cessation programs) outcomes. Included 20 monthly intervals: 6 pre implementation (Apr-Sept 2015) (PRE), 8 gradual implementation across all tumour sites (Oct 2015-May 2016), and 6 postb implementation (Jun 2016-Nov 2016) (POST). A time series segmented linear regression was conducted to evaluate changes in process of care outcomes (excluding the implementation period). Pre-post self-report patient outcome data was also compared. Results: We assessed data from n = 3785 (PRE) and n = 4726 (POST) new patients. Screening rates increased from 44% using the paper-based approach to 65% with CEASE (p = 0.0019). Referrals offered to smokers who were willing to quit increased from 24% to 100% (p &lt; 0.0001). Accepted referrals decreased from 45% to 26%; though the overall referral rate increased from 11% to 26% (p = 0.0001). The proportion of those using tobacco or attempting to quit did not differ at 3-months. However, engagement with the referral source increased from 4% to 62.5% (p &lt; 0.001). Conclusions: CEASE was successfully implemented across all clinics and resulted in improvements in overall screening and referral rates and engagement with referral services.
PRECEPT: an evidence assessment framework for infectious disease epidemiology, prevention and control
Authors: Thomas Harder, Anja Takla, Tim Eckmanns, Simon Ellis, Frode Forland, Roberta James, Joerg J Meerpohl, Antony Morgan, Eva Rehfuess, Holger Schünemann, Teun Zuiderent-Jerak, Helena de Carvalho Gomes, Ole Wichmann
Journal: Eurosurveillance (2017)

Decisions in public health should be based on the best available evidence, reviewed and appraised using a rigorous and transparent methodology. The Project on a Framework for Rating Evidence in Public Health (PRECEPT) defined a methodology for evaluating and grading evidence in infectious disease epidemiology, prevention and control that takes different domains and question types into consideration. The methodology rates evidence in four domains: disease burden, risk factors, diagnostics and intervention. The framework guiding it has four steps going from overarching questions to an evidence statement. In step 1, approaches for identifying relevant key areas and developing specific questions to guide systematic evidence searches are described. In step 2, methodological guidance for conducting systematic reviews is provided; 15 study quality appraisal tools are proposed and an algorithm is given for matching a given study design with a tool. In step 3, a standardised evidence-grading scheme using the Grading of Recommendations Assessment, Development and Evaluation Working Group (GRADE) methodology is provided, whereby findings are documented in evidence profiles. Step 4 consists of preparing a narrative evidence summary. Users of this framework should be able to evaluate and grade scientific evidence from the four domains in a transparent and reproducible way.
Neuropsychological sequelae of tamoxifen and exemestane after AC-chemotherapy in postmenopausal women with early breast cancer
Authors: C. M. Schilder, P. C. Eggens, W. Boogerd, F. S. van Dam, S. B. Schagen
Journal: Journal of Clinical Oncology (2007)

566 Background: Cognitive deficits and cognitive complaints in daily life have been associated with adjuvant chemotherapy in breast cancer survivors. The role of endocrine treatments with respect to these cognitive problems is unclear. Because estrogen deficiency may have adverse effects on certain cognitive functions, it is plausible that endocrine treatments affect cognitive functioning in addition to chemotherapy. The current aim was to investigate whether cognitive functioning of breast cancer patients treated with AC-chemotherapy and endocrine therapy differs from healthy controls and to examine possible distinctive effects between tamoxifen and exemestane. Methods: Postmenopausal breast cancer patients from the TEAM-trial, randomized to receive tamoxifen (n=30) or exemestane (n=51), underwent neuropsychological testing and were interviewed regarding cognitive complaints in daily life 1.5–4 years post AC- chemotherapy. At the time of testing, all patients still received their assigned endocrine treatment. Depression was measured with the Hopkins Symptom Checklist (HSCL), fatigue with the Multidimensional Fatigue Inventory (MFI). Healthy controls (n=48) underwent the same assessment. Results: After controlling for age and IQ, both tamoxifen and exemestane users scored significantly lower on ‘information processing speed’ than healthy controls (Reaction times; p = .023 and p = .008). Tamoxifen users scored significantly lower on ‘mental flexibility’ (Stroop Card 3; p = .007) and ‘category fluency’ (p = .&lt;0001) than healthy controls. A significant higher proportion of both tamoxifen and exemestane users reported memory problems in daily life compared to healthy controls (27.6 and 25.5% versus 6.3%, p = .02). Reported cognitive complaints did not correlate with test scores but with fatigue and depression. Conclusions: These results suggest that endocrine treatments combined with AC-chemotherapy have an effect on certain cognitive functions and provide indications for distinctive cognitive effects of different types of endocrine therapy. No significant financial relationships to disclose.
Nonpharmacologic Treatments for Depression in Older Adults
Authors: Laura N. Gitlin, José M. Aravena
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ZUMA-4 preliminary results: phase 1 study of KTE-C19 chimeric antigen receptor T cell therapy in pediatric and adolescent patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL)
Authors: D.W. Lee, A.S. Wayne, V. Huynh, R. Handgretinger, R. Pieters, G. Michele, A. Baruchel, T. Feuchtinger, Y. Bertrand, M. Hemiston, P.A. Brown, J. Rossi, Y. Jiang, L. Navale, S. Stout, J. Aycock, A. Mardiros, J. Wiezorek, R. Jain
Journal: Annals of Oncology (2017)
Abstract 14869: Survivors of Adult Out-of-Hospital Cardiac Arrest Are Likely to be Neurologically Intact Despite Prolonged Prehospital Resuscitation
Authors: Jefferson G Williams, Michael W Bachman, James W Box, D. Alan O'Neal, J. Brent Myers
Journal: Circulation (2015)

Introduction: Preliminary data suggest that adult out-of-hospital cardiac arrest (OHCA) patients may survive neurologically intact with duration of prehospital resuscitation (DOPR) exceeding previous guidelines. We assess how DOPR affects neurologically intact survival (NIS) from OHCA. Methods: We conducted an observational study of all OHCA patients in our urban/suburban advanced life support EMS system (pop 1,000,000) from 2005-2014. Excluded were resuscitations not attempted, age &lt; 16, trauma patients, and EMS-witnessed arrests. DOPR was measured from time of dispatch to end of prehospital resuscitation, defined by first return of spontaneous circulation, en-route hospital, or death. Primary outcome was NIS, defined as cerebral performance category (CPC) 1 or 2. Multiple modelling approaches including decision trees and multivariate logistic regression were used to determine predictors of NIS. Results: Of 3814 eligible OHCA, patients were: mean age 64.3 years and 60.4% male, 38.2% bystander witnessed, and 43.3% bystander assisted. Median time to first arriving professional response unit was 4.6 min (IQR 3.4-6.0). We controlled for resuscitation protocol changes over time, with median CPR fraction of 96% (IQR 93-96) and median compression rate 114 (103-137) during the most recent phase. Overall, 467 survived (12.2%) and 392 had NIS (83.9% of survivors). The median DOPR for NIS was 18 min (12-25), and the 90th percentile for NIS was 35 min, with 39 patients surviving neurologically intact with DOPR &gt; 35 min. The adjusted OR (95% CI) for the continuous variable DOPR was 0.99 (0.99-1.00) for NIS and 1.00 (0.99-1.00) for overall survival. The length of time that EMS was on scene also had an adjusted OR of 1.00 (1.00-1.00) for both survival and NIS. Significant predictors of NIS include age, initial rhythm, witnessed, basic airway, prehospital ROSC, and therapeutic hypothermia phase. Intermittent physiologic parameters such as End Tidal CO2 measured at 30 minutes after dispatch were not predictive. Limitations include the observational study design. CONCLUSIONS: In this retrospective analysis of OHCA, a majority of survivors were NIS regardless of DOPR. Further study should examine predictors of paramedics’ decision to extend resuscitation.
GW28-e0914 A Novel Mechanism Underlying Energy Metabolic Disorders in Failing Heart: Defective Branched Chain Amino Acid Catabolism-Induced Mitochondrial Metabolic Enzyme Hyper-Succinylation.
Authors: Fuyang Zhang, Xiyao Chen, Xinliang Ma, Jianming Pei, Ling Tao
Journal: Journal of the American College of Cardiology (2017)
First interim results of the radium-223 (Ra-223) REASSURE observational study: Analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza)
Authors: L.C. Harshman, J. Logue, C.N. Sternberg, S. Sundar, D. Schrijvers, M. Schostak, J. Sylvester, S. George, M. Tucci, C. Mantz, P. Borrega, P. Ziem, R. Concepcion, K. Miller, O. Sartor, J. Kalinovsky, Y. De Sanctis, B. Tombal
Journal: Annals of Oncology (2017)
Phase 1 Study of E7046, a PGE2 Receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment
Authors: D.S. Hong, A. Varga, A. Parikh, G. Shapiro, L. Reyderman, M. Ren, S. Dayal, T. Binder, C.E. Ooi, O. Ataman, A. Marabelle
Journal: Annals of Oncology (2017)
Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma
Authors: Wilson X Mai, Laura Gosa, Veerle W Daniels, Lisa Ta, Jonathan E Tsang, Brian Higgins, W Blake Gilmore, Nicholas A Bayley, Mitra Dehghan Harati, Jason T Lee, William H Yong, Harley I Kornblum, Steven J Bensinger, Paul S Mischel, P Nagesh Rao, Peter M Clark, Timothy F Cloughesy, Anthony Letai, David A Nathanson
Journal: Nature Medicine (2017)
Prospective comparison of RECIST and alternative response assessment criteria in the evaluation of metastatic renal cell cancer patients from phase II of the multi-centre randomised STAR trial
Authors: C. Kelly-Morland, J. Zhong, V. Goh, T. Wah, C. Ralph, F. Thistlethwaite, P. Patel, P. Nathan, T. Eisen, W. Gregory, L. McParland, H. Cool, K-L. Royle, E. Best, L. Whincup, F. Collinson, J. Brown
Journal: Annals of Oncology (2017)
Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes
Authors: A. Jassowicz, L. Liu, H. Huang, D.S. Hong, A. Naing, V. Subbiah, S.A. Piha-Paul, J. Toung, R. Vijayaraghavan, R. Zhang, H. Kang, S. Fu, A.M. Tsimberiodou, C. Lu, C. Eng, S. Moulder, S. Kopetz, R. Amaria, F. Meric-Bernstam, F. Janku
Journal: Annals of Oncology (2017)
Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms
Authors: C. Zhou, M. Wang, Y. Cheng, Y. Chen, X. Ye, Y. Sun, X. Huang, S. Patel, Y. Chen, Y-L. Wu
Journal: Annals of Oncology (2017)
A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study
Authors: M. Joerger, R.A. Soo, B.C. Cho, A. Navarro, C.M. Sayehli, H. Richly, D. Tai, D-W. Kim, J. Wolf, P. Cassier, S. Bender, P. Ellinghaus, S. Ince, P. Rajagopalan, M. Ocker, M. Schuler
Journal: Annals of Oncology (2017)
A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial
Authors: S. Postel-Vinay, D. Planchard, A.L. Ortega Granados, A. Gazzah, M.A. Sala Gonzalez, M. Majem, C.J. Camps, A. Abou-Lauvergne, J.-P. Pignon, J. Cadranel, J. Bennouna, F. Barlesi, M.R. Garcia Campelo, S. Viteri, B. Besse, J. Coves Sarto, B. Massuti Sureda, J.-C. Soria, R. Rosell
Journal: Annals of Oncology (2017)
Impaired β-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD
Authors: Farsad Afshinnia, Thekkelnaycke M. Rajendiran, Tanu Soni, Jaeman Byun, Stefanie Wernisch, Kelli M. Sas, Jennifer Hawkins, Keith Bellovich, Debbie Gipson, George Michailidis, Subramaniam Pennathur
Journal: Journal of the American Society of Nephrology (2017)

Studies of lipids in CKD, including ESRD, have been limited to measures of conventional lipid profiles. We aimed to systematically identify 17 different lipid classes and associate the abundance thereof with alterations in acylcarnitines, a metric of β -oxidation, across stages of CKD. From the Clinical Phenotyping Resource and Biobank Core (CPROBE) cohort of 1235 adults, we selected a panel of 214 participants: 36 with stage 1 or 2 CKD, 99 with stage 3 CKD, 61 with stage 4 CKD, and 18 with stage 5 CKD. Among participants, 110 were men (51.4%), 64 were black (29.9%), and 150 were white (70.1%), and the mean (SD) age was 60 (16) years old. We measured plasma lipids and acylcarnitines using liquid chromatography-mass spectrometry. Overall, we identified 330 different lipids across 17 different classes. Compared with earlier stages, stage 5 CKD associated with a higher abundance of saturated C16–C20 free fatty acids (FFAs) and long polyunsaturated complex lipids. Long-chain–to–intermediate-chain acylcarnitine ratio, a marker of efficiency of β -oxidation, exhibited a graded decrease from stage 2 to 5 CKD ( P &lt;0.001). Additionally, multiple linear regression revealed that the long-chain–to–intermediate-chain acylcarnitine ratio inversely associated with polyunsaturated long complex lipid subclasses and the C16–C20 FFAs but directly associated with short complex lipids with fewer double bonds. We conclude that increased abundance of saturated C16–C20 FFAs coupled with impaired β -oxidation of FFAs and inverse partitioning into complex lipids may be mechanisms underpinning lipid metabolism changes that typify advancing CKD.
Higher Risk of Vascular Dementia in Myocardial Infarction Survivors
Authors: Jens Sundbøll, Erzsébet Horváth-Puhó, Kasper Adelborg, Morten Schmidt, Lars Pedersen, Hans Erik Bøtker, Victor W. Henderson, Henrik Toft Sørensen
Journal: Circulation (2017)

Increased risk of dementia after myocardial infarction (MI) may be mediated by shared risk factors (eg, atherosclerosis) and post-MI stroke. We examined risk of dementia in 1-year survivors of MI.Using Danish medical registries, we conducted a nationwide population-based cohort study of all patients with first-time MI and a sex-, birth year-, and calendar year-matched general population comparison cohort without MI (1980-2012). Cox regression analysis was used to compute 1- to 35-year adjusted hazard ratios (aHRs) for dementia, controlled for matching factors and adjusted for comorbidities and socioeconomic status.We identified 314 911 patients with MI and 1 573 193 matched comparison cohort members randomly sampled from the general population (median age, 70 years; 63% male). After 35 years of follow-up, the cumulative incidence of all-cause dementia in the MI cohort was 9% (2.8% for Alzheimer disease, 1.6% for vascular dementia, and 4.5% for other dementias). Compared with the general population cohort, MI was not associated with all-cause dementia (aHR, 1.01; 95% confidence interval [CI], 0.98-1.03). Risk of Alzheimer disease (aHR, 0.92; 95% CI, 0.88-0.95) and other dementias (aHR, 0.98; 95% CI, 0.95-1.01) also approximated unity. However, MI was associated with higher risk of vascular dementia (aHR, 1.35; 95% CI, 1.28-1.43), which was substantially strengthened for patients experiencing stroke after MI (aHR, 4.48; 95% CI, 3.29-6.12).MI was associated with higher risk of vascular dementia throughout follow-up, and this association was stronger in patients with stroke. The risk of Alzheimer disease and other dementias was not higher in patients with MI.
Changements de l'immunité antidiphtérique spécifique selon l'âge en Pologne pendant les quarante dernières années
Authors: A Zakrzewska, A Galazka, D Rymkiewicz
Journal: Eurosurveillance (1997)

L'epidemie massive de diphterie en Russie et en Ukraine qui s'est etendue a tous les Nouveaux Etats Independants (NEI) de l'ex-URSS (1-5) a fait craindre la propagation possible de cette maladie dans d'autres pays. Cette crainte est justifiee car, dans beaucoup de pays industrialises, une grande partie de la population adulte est mal immunisee contre la diphterie.